Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma

Background/Aim: Radioactive iodine-refractory differentiated thyroid carcinoma (RR-DTC) has been treated with multi-kinase inhibitors (MKIs), e.g., sorafenib (SOR) and lenvatinib (LEN). We analyzed the outcomes of RR-DTC patients who underwent SOR or LEN treatment at Kuma Hospital. Patients and Meth...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:In Vivo
Hlavní autoři: ITO, YASUHIRO, ONODA, NAOYOSHI, KUDO, TAKUMI, MASUOKA, HIROO, HIGASHIYAMA, TAKUYA, KIHARA, MINORU, MIYA, AKIHIRO, MIYAUCHI, AKIRA
Médium: Artigo
Jazyk:Inglês
Vydáno: International Institute of Anticancer Research 2021
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045109/
https://ncbi.nlm.nih.gov/pubmed/33622902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12350
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky